Mineralys Therapeutics (MLYS) insider files to sell 14,055 shares

Rhea-AI Filing Summary

Mineralys Therapeutics insider David Rodman has filed a Form 144 notice to sell common stock. The filing covers 14,055 shares of Mineralys Therapeutics common stock to be sold through Merrill Lynch on the NASDAQ around 02/13/2026, with an aggregate market value of 385,732.29 and 79,139,956 shares outstanding.

The shares to be sold were acquired by exercising employee stock options, including 7,707 shares on 02/13/2026 through a broker-assisted cashless exercise and 6,348 shares on 02/12/2025 for cash. Over the past three months, Rodman has reported several sales of Mineralys common stock, including 192,715 shares on 01/05/2026 for gross proceeds of 6,749,100.06 and additional smaller transactions in January and February 2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	14055	385732.29	79139956	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	02/13/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			7707	02/13/2026	Broker assisted cashless exercise
Common stock	02/12/2025	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6348	02/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/12/2026	6348	205142.99
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/13/2026	7709	252469.75
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/14/2026	11367	370645.39
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	01/20/2026	416	13353.60
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/09/2026	2171	65585.91
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	02/12/2026	6349	184076.52

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Mineralys Therapeutics (MLYS) disclose?

The Form 144 notice discloses that David Rodman plans to sell 14,055 shares of Mineralys Therapeutics common stock. The planned sale has an aggregate market value of 385,732.29 and will be executed through Merrill Lynch on the NASDAQ around 02/13/2026.

How many Mineralys Therapeutics (MLYS) shares are covered by the new planned sale?

The notice covers a planned sale of 14,055 shares of Mineralys Therapeutics common stock. These shares have an aggregate market value of 385,732.29 and will be sold through Merrill Lynch, with NASDAQ listed as the securities exchange.

How were the Mineralys Therapeutics (MLYS) shares in the Form 144 acquired?

The shares were acquired through exercises of employee stock options from Mineralys Therapeutics, Inc. One block of 7,707 shares was obtained on 02/13/2026 via a broker-assisted cashless exercise, and another 6,348 shares was acquired on 02/12/2025 for cash.

What prior Mineralys Therapeutics (MLYS) stock sales has David Rodman reported in the last three months?

In the past three months, David Rodman reported several sales of Mineralys common stock, including 192,715 shares on 01/05/2026 for gross proceeds of 6,749,100.06. Additional smaller transactions occurred on multiple dates in January and February 2026.

What is the outstanding share count for Mineralys Therapeutics (MLYS) mentioned in the Form 144?

The filing states that 79,139,956 shares of Mineralys Therapeutics common stock are outstanding. This figure provides context for the planned sale of 14,055 shares but does not change the number of shares covered by the Form 144 notice.

Which broker and exchange are involved in the Mineralys Therapeutics (MLYS) Form 144 sale?

The planned sale will be executed through Merrill Lynch, listed at 225 Liberty St, Floor 37, New York, NY 10281. The securities exchange named for trading the 14,055 Mineralys common shares is the NASDAQ.